Welcome to our dedicated page for SQZ news (Ticker: SQZ), a resource for investors and traders seeking the latest updates and insights on SQZ stock.
SQZ Biotechnologies (SQZ) pioneers transformative cell therapies using its proprietary platform to reprogram immune cells. This dedicated news hub provides investors and medical professionals with essential updates on clinical developments, research breakthroughs, and corporate milestones.
Access verified information about SQZ's innovative approach to treating cancer, autoimmune disorders, and other complex conditions. Our curated collection features press releases on clinical trial progress, strategic collaborations with industry leaders, and financial updates that shape the company's trajectory.
Key content includes updates on SQZ's cell therapy pipeline, regulatory milestones, and peer-reviewed research findings. Discover how their MIT-originated technology enables precise immune cell engineering while maintaining rigorous safety standards.
Bookmark this page for streamlined access to SQZ's latest advancements in immunotherapy. Check regularly for objective reporting on technological innovations that could redefine modern medicine.
SQZ Biotechnologies (NYSE: SQZ) showcased promising preclinical research at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, highlighting their SQZ™ AACs and eAPC platforms. These findings suggest a synergistic effect when SQZ™ AACs were combined with cisplatin chemotherapy in HPV16+ cancer models, significantly increasing median survival. Additionally, their engineered tumor infiltrating lymphocytes (TILs) show potential without exogenous IL-2 support, enhancing therapeutic options for various cancer types. This innovative approach could broaden treatment accessibility and efficacy for patients.
SQZ Biotechnologies reported strong advancements in its clinical programs for Q3 2021, including the DSMB's recommendation to progress the SQZ-PBMC-HPV-101 trial into combination therapy with checkpoint inhibitors. The company anticipates an IND submission for the celiac disease TAC platform by Q3 2022, marking a significant expansion into autoimmune diseases. Financially, revenue decreased to $4.8 million from $6.1 million year-over-year, while the net loss increased to $22.5 million from $12.4 million, with research expenses rising to $20.5 million.
SQZ Biotechnologies (NYSE: SQZ) announced that the independent Data and Safety Monitoring Board has recommended advancing the SQZ-PBMC-HPV-101 clinical trial into the combination stage with checkpoint inhibitors. The highest dose monotherapy cohort has shown safety and immune response stimulation in patients with advanced HPV16+ tumors. This new phase is now open for enrollment, and the initiation will trigger a milestone payment from Roche. An oral presentation of the results is scheduled for December 9 at the ESMO-IO Congress in Geneva, Switzerland.
SQZ Biotechnologies (NYSE: SQZ) announced updates on three oncology programs to be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021 in Washington, D.C.. The company will showcase preclinical data on its AAC and eAPC platforms, highlighting their potential in developing diverse cell therapies against cancer. Presentations will include findings on T cell responses and tumor infiltrating lymphocytes. The full abstracts will be accessible on the SITC and SQZ websites.
SQZ Biotechnologies (NYSE: SQZ) announced its presentation at the Chardan 5th Annual Genetic Medicines Conference on
SQZ Biotechnologies (NYSE: SQZ) will present at the Cantor Global Healthcare Conference on
Illumina Ventures has closed its second investment fund, raising
SQZ Biotechnologies (NYSE: SQZ) announced its first clinical translation of the Tolerizing Antigen Carrier (TAC) platform targeting celiac disease, a serious autoimmune disorder. An IND filing is anticipated in Q3 2022. The TACs leverage existing red blood cell-based manufacturing to induce immune tolerance, showing ability to delete antigen-specific T cells and enhance regulatory T cells in preclinical trials. The company aims to expand this approach to other autoimmune diseases, while supporting ongoing oncology trials.
SQZ Biotechnologies (NYSE: SQZ) announced that CEO Armon Sharei will present at Citi’s 16th Annual Virtual Biopharma Conference on September 10 and at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13. Sharei's corporate overview will be featured, with one-on-one meetings scheduled at both events. The presentation on September 10 is set for 12:30-1:15 pm EDT, and the pre-recorded overview on September 13 will air from 7:00-7:20 am EDT. Webcast details will be accessible on SQZ's website.
SQZ Biotechnologies reported Q2 2021 revenue of $4.5 million, down from $6.0 million YoY, with a net loss of $19.1 million. Research and development expenses rose to $17.7 million due to planned initiatives. The company presented promising data at ASCO for its APC therapy, showing safety and signs of immune activity in patients. SQZ continues to advance its clinical programs and aims for an IND submission for its eAPC platform by year-end. With $185.1 million in cash, SQZ is well-funded through mid-2023.
FAQ
What is the market cap of SQZ (SQZ)?
